The Aleksandrovska University Hospital is a university hospital in Sofia, the capital of Bulgaria. It was founded in 1879 and was named after the Bulgarian Prince Alexander I Battenberg in October 1884. A military hospital between 1912 and 1919, it was the site where the Sofia Medical University was founded in 1917.

There are 1,100 beds in UMHAT "Alexandrovska", EAD.

During the past decade, UMHAT "Alexandrovska", EAD conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 20 clinical trials were completed, i.e. on average, 71.4% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 13 clinical trials were completed. i.e. 144.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UMHAT "Alexandrovska", EAD" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Sunovion" with 4 trials sponsored, "Allergan" with 3 trials sponsored, "Bayer" with 2 trials sponsored and "Biolex Therapeutics, Inc." with 2 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UMHAT "Alexandrovska", EAD" #1 collaborator was "Dermira, Inc." with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Cystic Fibrosis Foundation" with 1 trials as a collaborator and "Department of Health and Human Services" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "UMHAT "Alexandrovska", EAD" are "Schizophrenia" (4 trials), "Gastroparesis" (3 trials), "Multiple Sclerosis" (3 trials), "Atopic Dermatitis" (2 trials) and "COPD" (2 trials). Many other conditions were trialed in "UMHAT "Alexandrovska", EAD" in a lesser frequency.

Most popular intervention types in "UMHAT "Alexandrovska", EAD" are "Drug" (39 trials), "Biological" (5 trials), "Other" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Ocrelizumab" (3 trials), "Lebrikizumab" (2 trials), "Relamorelin" (2 trials) and "ribavirin" (2 trials). Other intervention names were less common.

The vast majority of trials in "UMHAT "Alexandrovska", EAD" are 44 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "UMHAT "Alexandrovska", EAD". undefined are not yet recruiting, 5 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in UMHAT "Alexandrovska", EAD, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in UMHAT "Alexandrovska", EAD, 1 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".